A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®
NCT ID: NCT00356421
Last Updated: 2009-09-02
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
58 participants
INTERVENTIONAL
2006-11-30
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 2 Diabetes
NCT00424411
A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®
NCT00391027
This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus
NCT00418522
Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
NCT00348374
A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus
NCT00367445
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Insulin lispro (Humalog)
Subcutaneous insulin regimen of pre-prandial insulin lispro and administration of insulin glargine QD.
Experimental
Inhaled Human Insulin (Exubera®)
Preprandial inhaled insulin regimen and administration of insulin glargine QD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inhaled Human Insulin (Exubera®)
Preprandial inhaled insulin regimen and administration of insulin glargine QD
Insulin lispro (Humalog)
Subcutaneous insulin regimen of pre-prandial insulin lispro and administration of insulin glargine QD.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Smoking
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Hamilton, New Jersey, United States
Pfizer Investigational Site
New Brunswick, New Jersey, United States
Pfizer Investigational Site
Vienna, , Austria
Pfizer Investigational Site
Vienna, , Austria
Pfizer Investigational Site
Edegem, , Belgium
Pfizer Investigational Site
Genk, , Belgium
Pfizer Investigational Site
Leuven, , Belgium
Pfizer Investigational Site
Aarhus, , Denmark
Pfizer Investigational Site
Kuopio, , Finland
Pfizer Investigational Site
Brest, , France
Pfizer Investigational Site
Corbeil-Essonnes, , France
Pfizer Investigational Site
Strasbourg, , France
Pfizer Investigational Site
Waterford, , Ireland
Pfizer Investigational Site
Amsterdam, , Netherlands
Pfizer Investigational Site
Stavanger, , Norway
Pfizer Investigational Site
Lisbon, , Portugal
Pfizer Investigational Site
Las Palmas, LAS Palmas de GRAN Canaria, Spain
Pfizer Investigational Site
Valencia, Valencia, Spain
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Bournemouth, Dorset, United Kingdom
Pfizer Investigational Site
Dundee, Tayside, United Kingdom
Pfizer Investigational Site
Birmingham, West Midlands, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A2171035
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.